We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-7.42%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.97B
AUM Growth
-$356M
Cap. Flow
+$116M
Cap. Flow %
2.92%
Top 10 Hldgs %
30.63%
Holding
140
New
5
Increased
76
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$22.5M
2
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$21.2M
3
DXCM icon
DexCom
DXCM
+$20.7M
4
IDXX icon
Idexx Laboratories
IDXX
+$20.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.3M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$18.8M
2
ISRG icon
Intuitive Surgical
ISRG
+$18M
3
IMRX icon
Immuneering
IMRX
+$17.6M
4
WHWK
Whitehawk Therapeutics
WHWK
+$13M
5
VERV
Verve Therapeutics
VERV
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.08%
2 Consumer Staples 1.53%
3 Industrials 0.67%
4 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STTK icon
126
Shattuck Labs
STTK
$686M
$1.34M 0.03%
313,499
– –
PSTX
127
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$1.3M 0.03%
289,754
– –
NUVB.WS
128
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$108K ﹤0.01%
134,028
– –
ABOS icon
129
Acumen Pharmaceuticals
ABOS
$179M
– –
-1,571,918
Closed -$10.6M
DAWN
130
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-381,939
Closed -$6.44M
IMRX icon
131
Immuneering
IMRX
$311M
– –
-1,089,816
Closed -$17.6M
NRIX icon
132
Nurix Therapeutics
NRIX
$2.71B
– –
-321,050
Closed -$9.29M
WHWK
133
Whitehawk Therapeutics
WHWK
$266M
– –
-538,835
Closed -$13M
2 3 4 5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Rock Springs Capital Management held 140 positions worth $3.97B, down 8.2% from $4.33B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rock Springs Capital Management's Q1 2022 filing shows 5 new, 76 increased, 8 reduced and 5 closed positions. Its largest new stake was Amylyx Pharmaceuticals: 998,307 shares worth $12.8M. The largest sale was HCA Healthcare, an estimated $18.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q1 2022 buy was Amylyx Pharmaceuticals: 998,307 shares worth $12.8M.
  • Rock Springs Capital Management added most to DexCom in Q1 2022, an estimated $20.7M increase.
  • Rock Springs Capital Management's biggest Q1 2022 reduction was HCA Healthcare, cutting an estimated $18.8M.
  • Rock Springs Capital Management fully exited Immuneering in Q1 2022, selling an estimated $17.6M.
  • Rock Springs Capital Management's ten largest holdings make up 31% of its $3.97B portfolio in Q1 2022.
  • Rock Springs Capital Management opened 5 new positions and closed 5 in Q1 2022.
  • Rock Springs Capital Management's portfolio value fell 8.2% quarter-over-quarter to $3.97B.

Based on Rock Springs Capital Management's 13F filing for Q1 2022, filed 16 May 2022.